European committee says Alzheimer’s treatment Leqembi shouldn’t get marketing approval

Click here to read more

The news keeps getting better and better for Xanamem...

Leqembi was forecast to earn $12.9 billion USD by 2028.

Click here to read more

With lower costs of production, a much lower cost to consumers, no medical transfusions or surgery, an excellent safety profile and the ability to dial up the dosage in a safe and non harmful way without significant side effects such as those present with Leqembi, Xanamem represents a drug that could be viewed by the FDA as a cost effective drug with an exemplary safety profile. Xanamem can even be taken alongside your other medication according to an independent review of medical professionals earlier this year.

With the potential to shorten the onset of Alzeihmer's at a much greater rate than Leqembi, what could Actinogen's pipeline in a pill be worth?

DYOR